Less than four months after the European Medicines Agency recommended in July not to grant marketing authorisation for Leqembi (lecanemab) for the treatment of Alzheimer's disease, the EMA's Committee for Medicinal Products for Human Use (CHMP) has reassessed the available evidence to conclude that the benefits outweigh the risks
The favorable profile refers to their exemplary efficacy in addressing hyperglycemia, their safety, low risk of hypoglycemia, their multilevel pathophysiological superiority, weight loss and the reported benefits in CVD reduction
Fitzgerald R, Bass LM, Goldberg DJ, Graivier MH, Lorenc ZP
You might be suitable for Klinic's semaglutide weight loss program if you're living in Fond du Lac and have a BMI of 30 or more, or a BMI of 27+ alongside a weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol